Coca-Cola Beverages PLC posts 6.5% drop in sales

Article Abstract:

Coca-Cola Beverages PLC of Europe earned sales 6.5% lower to just 569.6 million pounds sterling, or $971.9 million, during the first six months of 1998 due to the Russian economic crisis. Chairman and Chief Executive Neville Isdell noted that the bottling company saw local currencies in Ukraine and Belarus devalued by the economic troubles of Russia, which, in turn, affected the prices of key raw materials. Isdell indicated that the 11 other nations where Coca-Cola Beverages maintains operations have not been affected. Coca-Cola Co. has a 50.1% stake in Coca-Cola Beverages.

Comment:

Earns sales 6.5% lower to just 569.6 mil pounds sterling or $971.9 mil during the first six months of 1998

Sales, profits & dividends, Canned & Bottled Soft Drinks, Soft Drink Manufacturing, Soft drinks, Coca-Cola Beverages PLC

---

Racal, colt unveil communications link; agreement may signal more deals in the sector

Article Abstract:

Racal Electronics PLC has launched a communications tie-up between its Racal Telecom unit and Colt Telecom PLC as part of its expansion plans in Europe. Most shares were hiked on the news of the partnership because of the spate of mergers, that has struck the UK telecom sector. Analysts, however, cautioned investors against thinking that a full-scale merger is in the wraps. A senior analyst believes the agreement has an impact in terms of the two entities' capability to come up with deals at a rapid period of development in the industry.

Comment:

Has launched a communications tie-up with the Racal Telecom unit of Racal Electronics PLC

Wired Telecommunications Carriers, Strategic alliances, Data Transmission Services, Telecommunications industry, Racal Electronics PLC, Telecommunications transmission technologies, Colt Telecom PLC

---

SmithKline hopes new diabetes drug will fuel growth

Article Abstract:

SmithKline Beecham PLC launched its new Avandia diabetes drug in the US. The product launch occurred after the company won approval from the US Food and Drug Administration (FDA). SmithKline would have a strong financial position if its Avandia drug proves to be successful along with its new Paxil/Seroxat antidepressant drug. The success of the drugs would enable the company to either remain independent or seek for a merger.

Comment:

Launches new Avandia diabetes drug in US

United States, Product introduction, Pharmaceutical Preparation Manufacturing, Antidiabetic Preparations, Pharmaceutical industry, Abstract, Hypoglycemic agents, SmithKline Beecham PLC

Similar abstracts:

• Abstracts: Fiat gives some details of Romiti's retirement. Olivetti names candidates for Telecom Italia board. Telecom Italia names Colaninno
• Abstracts: City Hotels pret c der tous ses hotels europ ens TTS sur la route de la diversification Cobepa takes 33% of zetes
• Abstracts: La BBL revoit en baisse ses pr visions/ La Royale Belge vend ses Electrafina et ses Suez
• Abstracts: KLM pilots can't strike in solidarity, judge rules. Bidding starts for French airline, amid rescue of credit Lyonnais
• Abstracts: British Midland secures options on long-haul jets. BA won't comment on aircraft report

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.